Targeted delivery of platinum-taxane combination therapy in ovarian cancer

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 651-659

  Desale, Swapnil S ^a   Soni, Kruti S ^a   Romanova, Svetlana ^a   Cohen, Samuel M ^b   Bronich, Tatiana K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cisplatin; Combination drug delivery; Nanogels; Ovarian cancer; Paclitaxel; Receptor targeting

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BLOCK COPOLYMERS; CHEMOTHERAPY; DRUG PRODUCTS; LIGANDS; NANOSTRUCTURED MATERIALS; PLATINUM; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; TUMORS;

CIS-PLATIN; NANOGELS; OVARIAN CANCERS; PACLITAXEL; RECEPTOR TARGETING;

DISEASES;

CISPLATIN; FOLATE RECEPTOR; FOLIC ACID; MACROGOL; NANOCARRIER; NANOGEL; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; FOLATE TRANSPORTER; GEL; MACROGOL DERIVATIVE; NANOPARTICLE; PEPTIDE; POLYGLUTAMIC ACID; POLYMER; POLYPHENYLALANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURFACE PROPERTY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GEL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CISPLATIN; DRUG CARRIERS; FEMALE; FOLIC ACID; FOLIC ACID TRANSPORTERS; GELS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; POLYMERS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949513310     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.007     Document Type: Article

References (46)

1. J. Jia, F. Zhu, X. Ma, Z.W. Cao, Y.X. Li, and Y.Z. Chen Mechanisms of drug combinations: interaction and network perspectives Nat. Rev. Drug Discov. 8 2009 111 128
2. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 2006 34 43
3. R. Agarwal, and S.B. Kaye Ovarian cancer: Strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 3 2003 502 516
4. A.V. Kabanov, and S.V. Vinogradov Nanogels as pharmaceutical carriers: finite networks of infinite capabilities Angew. Chem. Int. Ed. Engl. 48 2009 5418 5429
5. M. Talelli, M. Barz, C.J. Rijcken, F. Kiessling, W.E. Hennink, and T. Lammers Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation Nano Today 10 2015 93 117
6. C.J. Rijcken, C.J. Snel, R.M. Schiffelers, C.F. van Nostrum, and W.E. Hennink Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies Biomaterials 28 2007 5581 5593
7. J. Peng, T. Qi, J. Liao, B. Chu, Q. Yang, W. Li, Y. Qu, F. Luo, and Z. Qian Controlled release of cisplatin from pH-thermal dual responsive nanogels Biomaterials 34 2013 8726 8740
8. W. Jin, P. Xu, Y. Zhan, Y. Shen, E.A. Van Kirk, B. Alexander, W.J. Murdoch, L. Liu, and D.D. Isaak Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly (β-aminoester)-graft-PEG for cancer chemotherapy Drug Deliv. 14 2007 279 286
9. P. Liu, M. Gou, T. Yi, X. Qi, C. Xie, S. Zhou, H. Deng, Y. Wei, and X. Zhao The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer Int. J. Oncol. 41 2012 1504 1512
10. S.S. Desale, S.M. Cohen, Y. Zhao, A.V. Kabanov, and T.K. Bronich Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer J. Control. Release 171 2013 339 348
11. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
12. B.S. Pattni, and V.P. Torchilin Targeted drug delivery systems: strategies and challenges Padma V. Devarajan, Sanyog Jain, Targeted Drug Delivery: Concepts and Design 2015 Springer New York 3 38
13. F. Danhier, O. Feron, and V. Préat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
14. S. Hong, P.R. Leroueil, I.J. Majoros, B.G. Orr, J.R. Baker, and M.M. Banaszak Holl The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform Chem. Biol. 14 2007 107 115
15. M. Talelli, C.J. Rijcken, S. Oliveira, R. van der Meel, P.M.v.B. en Henegouwen, T. Lammers, C.F. van Nostrum, G. Storm, and W.E. Hennink Reprint of "nanobody - shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting" J. Control. Release 153 2011 93 102
16. Y. Wang, R. Zhao, R.G. Russell, and I.D. Goldman Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis Biochim. Biophys. Acta 1513 2001 49 54
17. S.K. Desmoulin, Z. Hou, A. Gangjee, and L.H. Matherly The human proton-coupled folate transporter: biology and therapeutic applications to cancer Cancer Biol. Ther. 13 2012 1355 1373
18. Y. Lu, and P.S. Low Folate-mediated delivery of macromolecular anticancer therapeutic agents Adv. Drug Deliv. Rev. 64 2012 342 352
19. I.B. Vergote, C. Marth, and R.L. Coleman Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications Cancer Metastasis Rev. 34 2015 41 52
20. R.W. Naumann, R.L. Coleman, R.A. Burger, E.A. Sausville, E. Kutarska, S.A. Ghamande, N.Y. Gabrail, S.E. DePasquale, E. Nowara, and L. Gilbert PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer J. Clin. Oncol. 31 2013 4400 4406
21. R. Morris, R. Joyrich, R. Naumann, N. Shah, A. Maurer, H. Strauss, J. Uszler, J. Symanowski, P. Ellis, and W. Harb Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide) Ann. Oncol. 25 2014 852 858
22. I. Vergote, D. Armstrong, G. Scambia, K. Fujiwara, V. Gorbunova, C. Schweizer, S. Weil, A. Barnias, C. Poole, and J. Sehouli Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse Int. J. Gynecol. Cancer 23 2013 11 (Supplement 1)
23. E.I. Sega, and P.S. Low Tumor detection using folate receptor-targeted imaging agents Cancer Metastasis Rev. 27 2008 655 664
24. N. Parker, M.J. Turk, E. Westrick, J.D. Lewis, P.S. Low, and C.P. Leamon Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay Anal. Biochem. 338 2005 284 293
25. R.E. Fisher, B.A. Siegel, S.L. Edell, N.M. Oyesiku, D.E. Morgenstern, R.A. Messmann, and R.J. Amato Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors J. Nucl. Med. 49 2008 899 906
26. N.V. Nukolova, H.S. Oberoi, S.M. Cohen, A.V. Kabanov, and T.K. Bronich Folate-decorated nanogels for targeted therapy of ovarian cancer Biomaterials 32 2011 5417 5426
27. S.S. Desale, S.M. Raja, J.O. Kim, B. Mohapatra, K.S. Soni, H. Luan, S.H. Williams, T.A. Bielecki, D. Feng, and M. Storck Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models J. Control. Release 208 2015 59 66
28. M. Ferrari, M.C. Fornasiero, and A.M. Isetta MTT colorimetric assay for testing macrophage cytotoxic activity in vitro J. Immunol. Methods 131 1990 165 172
29. C.P. Leamon, J.A. Reddy, R. Dorton, A. Bloomfield, K. Emsweller, N. Parker, and E. Westrick Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates J. Pharmacol. Exp. Ther. 327 2008 918 925
30. S.A. Ferreira, F.M. Gama, and M. Vilanova Polymeric nanogels as vaccine delivery systems Nanomedicine 9 2013 159 173
31. Y. Shi, M.J. van Steenbergen, E.A. Teunissen, L.S. Novo, S. Gradmann, M. Baldus, C.F. van Nostrum, and W.E. Hennink Π-Π stacking increases the stability and loading capacity of thermosensitive polymeric micelles for chemotherapeutic drugs Biomacromolecules 14 2013 1826 1837
32. Y. Shi, R. van der Meel, B. Theek, E. Oude Blenke, E.H. Pieters, M.H. Fens, J. Ehling, R.M. Schiffelers, G. Storm, and C.F. van Nostrum Complete regression of xenograft tumors upon targeted delivery of paclitaxel via Π-Π stacking stabilized polymeric micelles ACS Nano 9 2015 3740 3752
33. T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. Nakatomi, M. Yokoyama, K. Kataoka, and T. Kakizoe NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246
34. J. Logie, C.K. McLaughlin, R.Y. Tam, and M.S. Shoichet Innovative use of the taxol binding peptide overcomes key challenges of stable and high drug loading in polymeric nanomicelles Chem. Commun. (Camb.) 51 2015 12000 12003
35. N. Chida, Y. Hirasawa, T. Ohkawa, Y. Ishii, Y. Sudo, K. Tamura, and S. Mutoh Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor Eur. J. Pharmacol. 509 2005 71 76
36. K. Jaaback, and N. Johnson Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Cochrane Database Syst. Rev. 1 2006 CD005340
37. D.L. Chan, D.L. Morris, A. Rao, and T.C. Chua Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy Cancer Manag. Res. 4 2012 413
38. B.W. Yin, and K.O. Lloyd Molecular cloning of the CA125 ovarian cancer antigen identification as a new mucin, MUC16 J. Biol. Chem. 276 2001 27371 27375
39. D. Gupta, and C.G. Lis Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature Nutr. J. 9 2010 69 10.1186/1475-2891-9-69
40. R.C. Bast Jr., T.L. Klug, E.S. John, E. Jenison, J.M. Niloff, H. Lazarus, R.S. Berkowitz, T. Leavitt, C.T. Griffiths, and L. Parker A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N. Engl. J. Med. 309 1983 883 887
41. T.J. Shaw, M.K. Senterman, K. Dawson, C.A. Crane, and B.C. Vanderhyden Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer Mol. Ther. 10 2004 1032 1042
42. M.F. Burbridge, L. Kraus-Berthier, M. Naze, A. Pierre, G. Atassi, and N. Guilbaud Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity Int. J. Oncol. 15 1999 1155 1217
43. F. Kraeber-Bodéré, A. Mishra, P. Thédrez, A. Faivre-Chauvet, M. Bardiès, S. Imai, J. Le Boterff, and J.-F. Chatal Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer Eur. J. Nucl. Med. 23 1996 560 567
44. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687
45. Y. Mizumura, Y. Matsumura, T. Hamaguchi, N. Nishiyama, K. Kataoka, T. Kawaguchi, W.J.M. Hrushesky, F. Moriyasu, and T. Kakizoe Cisplatin incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity Cancer Sci. 92 2001 328 336
46. P.S. Low, W.A. Henne, and D.D. Doorneweerd Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases Acc. Chem. Res. 41 2007 120 129